Zhang Qi, Lei Jianyong, Ding Yuedi, Chen Yun, Qu Lin, Chen Shuxian, Jin Jian
Department of Cellular and Molecular Pharmacology, School of Medicine and Pharmacology, Jiangnan University, Wuxi 214122, China.
Sheng Wu Gong Cheng Xue Bao. 2009 Nov;25(11):1746-52.
In order to obtain enough fusion protein for developing preclinical studies of IFNbeta-HAS, we screened Pichia pastoris transformants expressing high-level protein by immunology method. The yield of IFNbeta-HSA was about 500 mg/L by fed-batch fermentation. The purity of IFNbeta-HSA reached 96% through the steps of ultrafiltration, Blue Sepharose FF, Ni2+-IMAC and DEAE Sepharose FF. Analysis of Western blotting showed that IFNbeta-HSA had the antigenicity of IFNbeta and HSA. The specific activity was about 1.96 x 10(7) IU/mg by standard survival activity test on WISH cells challenged with VSV virus. This study provided a method to produce IFNbeta-HSA.
为了获得足够的融合蛋白用于开展IFNβ-HAS的临床前研究,我们通过免疫学方法筛选了表达高水平蛋白的毕赤酵母转化子。通过补料分批发酵,IFNβ-HSA的产量约为500 mg/L。经过超滤、Blue Sepharose FF、Ni2+-IMAC和DEAE Sepharose FF步骤,IFNβ-HSA的纯度达到了96%。蛋白质印迹分析表明,IFNβ-HSA具有IFNβ和HSA的抗原性。通过对受VSV病毒攻击的WISH细胞进行标准存活活性测试,其比活性约为1.96×10(7) IU/mg。本研究提供了一种生产IFNβ-HSA的方法。